BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 29426004)

  • 1. Cell membrane-coated nanocarriers: the emerging targeted delivery system for cancer theranostics.
    Bose RJ; Paulmurugan R; Moon J; Lee SH; Park H
    Drug Discov Today; 2018 Apr; 23(4):891-899. PubMed ID: 29426004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
    Zhang W; Liu M; Liu A; Zhai G
    Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrid protein-inorganic nanoparticles: From tumor-targeted drug delivery to cancer imaging.
    Elzoghby AO; Hemasa AL; Freag MS
    J Control Release; 2016 Dec; 243():303-322. PubMed ID: 27794493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites.
    Attia MF; Anton N; Wallyn J; Omran Z; Vandamme TF
    J Pharm Pharmacol; 2019 Aug; 71(8):1185-1198. PubMed ID: 31049986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From The Mine to Cancer Therapy: Natural and Biodegradable Theranostic Silicon Nanocarriers from Diatoms for Sustained Delivery of Chemotherapeutics.
    Maher S; Kumeria T; Wang Y; Kaur G; Fathalla D; Fetih G; Santos A; Habib F; Evdokiou A; Losic D
    Adv Healthc Mater; 2016 Oct; 5(20):2667-2678. PubMed ID: 27594524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell membrane-coated nanosized active targeted drug delivery systems homing to tumor cells: A review.
    He Z; Zhang Y; Feng N
    Mater Sci Eng C Mater Biol Appl; 2020 Jan; 106():110298. PubMed ID: 31753336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid quantum dot-based theranostic nanomedicines for tumor-targeted drug delivery and cancer imaging.
    Zayed DG; AbdElhamid AS; Freag MS; Elzoghby AO
    Nanomedicine (Lond); 2019 Feb; 14(3):225-228. PubMed ID: 30652951
    [No Abstract]   [Full Text] [Related]  

  • 9. Calcium phosphate nanocarriers for drug delivery to tumors: imaging, therapy and theranostics.
    Huang D; He B; Mi P
    Biomater Sci; 2019 Oct; 7(10):3942-3960. PubMed ID: 31414096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in aptamer-armed multimodal theranostic nanosystems for imaging and targeted therapy of cancer.
    Vandghanooni S; Eskandani M; Barar J; Omidi Y
    Eur J Pharm Sci; 2018 May; 117():301-312. PubMed ID: 29499349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Cell-Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting and Drug Delivery.
    Xie Z; Su Y; Kim GB; Selvi E; Ma C; Aragon-Sanabria V; Hsieh JT; Dong C; Yang J
    Small; 2017 Mar; 13(10):. PubMed ID: 28026115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.
    Huynh NT; Roger E; Lautram N; Benoît JP; Passirani C
    Nanomedicine (Lond); 2010 Nov; 5(9):1415-33. PubMed ID: 21128723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities.
    Ruman U; Fakurazi S; Masarudin MJ; Hussein MZ
    Int J Nanomedicine; 2020; 15():1437-1456. PubMed ID: 32184597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injectable Drug-Loaded Nanocarriers for Lung Cancer Treatments.
    Yu HP; Aljuffali IA; Fang JY
    Curr Pharm Des; 2017; 23(3):481-494. PubMed ID: 28292243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer.
    Thorat ND; Townley HE; Patil RM; Tofail SAM; Bauer J
    Drug Discov Today; 2020 Jul; 25(7):1245-1252. PubMed ID: 32371139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of theranostic agents. [Corrected].
    Wang H; Agarwal P; Zhao S; Yu J; Lu X; He X
    Nat Commun; 2015 Dec; 6():10081. PubMed ID: 26621191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prussian blue nanoparticles and their analogues for application to cancer theranostics.
    Patra CR
    Nanomedicine (Lond); 2016 Mar; 11(6):569-72. PubMed ID: 26911239
    [No Abstract]   [Full Text] [Related]  

  • 18. Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery.
    Sun D; Chen J; Wang Y; Ji H; Peng R; Jin L; Wu W
    Theranostics; 2019; 9(23):6885-6900. PubMed ID: 31660075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanocarriers for cancer-targeted drug delivery.
    Kumari P; Ghosh B; Biswas S
    J Drug Target; 2016; 24(3):179-91. PubMed ID: 26061298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copper sulfide nanoparticle-based localized drug delivery system as an effective cancer synergistic treatment and theranostic platform.
    Hou L; Shan X; Hao L; Feng Q; Zhang Z
    Acta Biomater; 2017 May; 54():307-320. PubMed ID: 28274767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.